Fluorescent Heterocyclic Compound-Loaded Bi2Se3-Polysorbate Nanoparticles for Targeted Therapy in Non-Small Cell Lung Cancer

This study introduces a novel approach for non-small cell lung Cancer (NSCLC) treatment by developing Bi₂Se₃-Polysorbate nanoparticles as a multifunctional platform for photothermal therapy and targeted drug delivery. The Bi₂Se₃-Polysorbates nanoparticles are engineered as innovative photosensitive drug carriers, enhancing biocompatibility through the combination of Bi₂Se₃ and Polysorbates. Characterization techniques such as Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and ultraviolet-visible (UV-Vis) spectroscopy confirm the successful synthesis of the nanoparticles. In a breakthrough step, these nanoparticles are combined with a novel heterocyclic drug (drug-1), verified by single-crystal analysis, to create the Bi₂Se₃-Polysorbates@drug-1 composite. Biological evaluations show that the system significantly inhibits cell proliferation in NSCLC cells, and molecular docking studies reveal that drug-1 interacts with the target protein through hydrogen bonds, halogen bonds, and hydrophobic interactions, suggesting promising anti-cancer activity. This research presents a novel multifunctional nanoplatform for effective drug delivery and offers a new strategy for the treatment of NSCLC, demonstrating significant advancements in Cancer therapy.

Bi2Se3-Polysorbates; Heterocyclic; NSCLC.